Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events...

Descripción completa

Detalles Bibliográficos
Autores principales: Husain, Mansoor, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://www.ncbi.nlm.nih.gov/pubmed/32998732
http://dx.doi.org/10.1186/s12933-020-01106-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://www.ncbi.nlm.nih.gov/pubmed/32998732
http://dx.doi.org/10.1186/s12933-020-01106-4

Ejemplares similares